It was an honor to meet Professor Mads Krogsgaard Thomsen to discuss the results from seven phase 3a PIONEER clinical trials for oral semaglutide in patients with type 2 diabetes, including the cardiovascular outcomes trial (PIONEER 6) at the highly anticipated symposium highlighted by the ADA 2019 annual meeting.
Filmed at the American Diabetes Association (ADA) annual meeting 2019, San Francisco, USA
1. What are the advantages of oral semaglutide compared to existing glucagon-like peptide-1 (GLP-1) analogues? (0:05)
2. Could you give us an overview on the data on oral semaglutide that are being presented at this meeting? (0:36)
3. What were the findings of oral semaglutide on weight loss? (1:37)
4. The PIONEER studies investigated a number of combined therapeutic approaches. Which were the most promising? (2:24)
5. Which patients are most likely to benefit from oral semaglutide? (3:12)
Professor Mads Krogsgaard Thomsen has no conflicts of interest in relation to this video.
touchENDO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Diabetes
Chantal Mathieu: Research highlights from 2022
We were delighted to speak with our editorial board member Prof. Chantal Mathieu (University Hospital Gasthuisberg Leuven, Leuven, Belgium) around this year’s research highlights in diabetes and what to look out for in 2023. Questions What are the key clinical highlights from 2022 in the field of diabetes? (0:16) What are the hot topics and […]
José García-Tirado, DTM 2022: RocketAP in Practice: Results from Pilot and Feasibility Trials
In this touchENDOCRINOLOGY interview, Dr José García-Tirado (University of Virginia, Charlottesville, VA, USA) gives an overview of RocketAP and discusses how the RocketAP compares to the USS-Virginia system and also what the next steps in the clinical development of the Rocket AP will be. The abstract entitled: ‘RocketAP in Practice: Results from Pilot and Feasibility […]
José García-Tirado, DTM 2022: Challenges in the development of artificial pancreas systems
An artificial pancreas is a system made of three parts that work together to mimic how a healthy pancreas controls blood glucose in the body. In this touchENDOCRINOLOGY interview, Dr José García-Tirado (University of Virginia, Charlottesville, VA, USA) discusses the major challenges in the development of artificial pancreas systems. The abstract entitled: ‘RocketAP in Practice: Results from Pilot […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!